ZEISS PALM MicroBeam IV module Rel 4.2

ZEISS PALM MicroBeam IV 模块 Rel 4.2

• 批准号: 8052425
• 负责人: Sashwati Roy
• 金额: $ 29.69万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-15 至 2012-10-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052425
• 关键词: Academic Medical Centers; Admixture; Affect; Applications Grants; Area; Award; Biology; Cells; Child; Clinical Sciences; Clinical and Translational Science Awards; Commit; Communities; Core Facility; DNA; Development; Diagnostics Research; Direct Costs; Dissection; Equipment; Extramural Activities; Faculty; Funding; Future; Gene Expression; Germany; Goals; Heterogeneity; Housing; Institution; Lasers; Legal patent; Methodology; Methods; Microdissection; Minor; Molecular; Molecular Profiling; National Center for Research Resources; Ohio; Outcome; Pathology; Population; Productivity; Proteins; Proteomics; RNA; Request for Proposals; Research; Research Personnel; Research Project Grants; Resources; Sampling; Technology; Tissues; Translational Research; United States National Institutes of Health; Universities; indexing; instrument; instrumentation; novel; pressure; programs; response

DESCRIPTION (provided by applicant): This proposal requests NCRR support for the acquisition of state-of-the-art PALM MicroBEAM IV laser capture micro-dissection instrument (PALM MicroBeam) from Zeiss (P.A.L.M. Microlaser Technologies, Carl Zeiss Group, Bernried, Germany). This equipment would be the first laser capture equipment for shared use in the Ohio State University (OSU). The entire OSU or nearby Nationwide Children's do not have a Laser Capture Micro-dissection (LCM) core facility. The requested instrument will be housed in Laser Capture Molecular Core facilities (https://lcm.osu.edu/index.cfm) in the Ohio State University Medical Center (OSUMC). ). Space and relevant resources have been committed for the proposed core in response to faculty requests. In May, 2008 OSU was awarded the prestigious NIH Clinical and Translational Science Award (CTSA). LCM novel methodology development was a priority area in this award. The PI together with two other investigators was awarded research grant to develop proteomics and miR profiling methods from LCM samples. These methods are now ready for dissemination; OSU CTSA has announced matching funds for dissemination of methodology developed via Laser Capture Molecular Core to OSU investigators. The requested PALM MicroBeam has the patented laser microdissection and pressure catapulting (LMPC) technology. The molecular examination of pathologically altered cells and tissues at the DNA, RNA, and protein level has revolutionized research and diagnostics in pathology. However, the inherent heterogeneity of primary tissues with an admixture of various reactive cell populations can affect the outcome and interpretation of molecular studies. Particularly suited to study spatially resolved biology, LMPC enables the investigator to isolate samples of pure cell populations as small as single cells or even sub cellular fragments for further molecular profiling (gene expression, proteomics). The equipment is expected to directly enhance the productivity of a minimum of 14 (8 major users and 6 minor users) currently funded federal research grants totaling > $ 2.5 million in annual direct costs. The long term goals of the core facility are to provide diverse research community of OSUMC and affiliated research institutions with the latest LCM technology and applications. The funding of this instrumentation grant application for LCM will transform the capability of the federally funded research programs at the OSU, increasing their productivity and competitiveness for future extramural funding that can impact NIH and/or other extra mural funded research at OSU. PUBLIC HEALTH RELEVANCE: PALM MicroBeam IV is high-throughput laser microdissection (LCM) equipment. Using this technology, individual cells and specific regions can be captured from clinically relevant small tissue section for genomic and proteomic analyses. The technology is best suited and is essential for human health relevant translational research.

描述（由申请人提供）：本提案请求 NCRR 支持从 Zeiss（P.A.L.M. Microlaser Technologies，Carl Zeiss Group，Bernried，德国）采购最先进的 PALM MicroBEAM IV 激光捕获显微解剖仪器 (PALM MicroBeam)。该设备将是俄亥俄州立大学 (OSU) 首个共享使用的激光捕获设备。整个 OSU 或附近的全国儿童医院没有激光捕获显微解剖 (LCM) 核心设施。所需的仪器将安置在俄亥俄州立大学医学中心 (OSUMC) 的激光捕获分子核心设施 (https://lcm.osu.edu/index.cfm) 中。 ）。应教师的要求，已为拟议的核心项目提供了空间和相关资源。 2008 年 5 月，俄勒冈州立大学荣获著名的 NIH 临床和转化科学奖 (CTSA)。 LCM 新颖方法的开发是该奖项的优先领域。该 PI 与其他两名研究人员一起获得了研究经费，用于开发 LCM 样本的蛋白质组学和 miR 分析方法。这些方法现已准备好进行传播； OSU CTSA 已宣布提供配套资金，用于向 OSU 研究人员传播通过激光捕获分子核心开发的方法。所要求的 PALM MicroBeam 拥有获得专利的激光显微切割和压力弹射 (LMPC) 技术。在 DNA、RNA 和蛋白质水平上对病理改变的细胞和组织进行分子检查彻底改变了病理学的研究和诊断。然而，原代组织与各种反应性细胞群混合的固有异质性可能会影响分子研究的结果和解释。 LMPC 特别适合研究空间分辨生物学，使研究人员能够分离小至单细胞甚至亚细胞碎片的纯细胞群样本，以进行进一步的分子分析（基因表达、蛋白质组学）。该设备预计将直接提高至少 14 个（8 个主要用户和 6 个次要用户）目前资助的联邦研究经费每年直接成本总计超过 250 万美元的生产力。核心设施的长期目标是为 OSUMC 及其附属研究机构的多元化研究团体提供最新的 LCM 技术和应用。 LCM 仪器拨款申请的资助将改变 OSU 联邦资助的研究项目的能力，提高其生产力和未来校外资助的竞争力，这可能会影响 NIH 和/或 OSU 其他校外资助的研究。 公共健康相关性：PALM MicroBeam IV 是高通量激光显微切割 (LCM) 设备。使用该技术，可以从临床相关的小组织切片中捕获单个细胞和特定区域，以进行基因组和蛋白质组分析。该技术最适合人类健康相关的转化研究，并且是必不可少的。